<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asxannounc0502251.txt
<TEXT>
UNITED STATES
SECURITIES	AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2005

Novogen Limited
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes   No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
	82- ________________	.1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 24 February, 2005  By /s/Ronald Lea Erratt Company Secretary


ASX & MEDIA RELEASE
25 FEBRUARY, 2005

NOVOGEN LIMITED APPOINTS NEW DIRECTOR

Listed pharmaceutical company, Novogen Limited
(ASX: Novogen Nasdaq: NVGN)  has appointed
Mr Geoffrey Leppinus as a Non-executive Director of the Company.

Mr Leppinus is a former Senior Advisory and Audit Partner with
the international accounting firm KPMG and has over 30 years'
experience in professional accounting, audit and finance.

Novogen Chairman, Mr Philip Johnston, said Mr Leppinus
would bring a vast knowledge of finance and commercial experience
to the Board.

"Geoff Leppinus has considerable experience in all aspects of
large public company finance and this experience and knowledge
will be a welcome addition to the Board as the Company
continues the commercialisation and internationalisation
of its activities," Mr Johnston said.

Mr Leppinus joins a board comprising Non-executive
Chairman Mr Philip Johnston, Managing Director
Mr Christopher Naughton, Executive Director Dr Graham Kelly,
and Non-executive Directors Professor Paul Nestel AO,
Dr Leanna Read and Mr Peter Simpson.
He will become an independent director on the
Audit Committee of the Company.

Novogen has an international business in the research
and development of drugs derived from its phenolic technology
platform.  The Company manages its research and development
programs utilising the expertise and clinical research
capabilities of universities and hospitals in Australia,
the US and other key international locations.
The Novogen group of companies includes the listed
subsidiary Marshall Edwards Inc. (Nasdaq: MSHL LSE-AIM:MSH).

More information on the Novogen Group can be found
at www.marshalledwardsinc.com and www.novogen.com .


Statements included in this press release that are
not historical in nature are forward-looking
statements within the meaning of the safe harbor
provisions of the Private Securities Litigation
Reform Act of 1995.  You should be aware that
our actual results could differ materially
from those contained in the forward-looking
statements, which are based on managements current
expectations and are subject to a number of risks
and uncertainties, including, but not limited to,
our failure to successfully commercialize our
product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such
approval, of our product candidates; uncertainties
in clinical trial results; our inability to maintain
or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products;
competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property
to operate our business; our inability to operate our
business without infringing the patents and proprietary
rights of others; general economic conditions; the
failure of any products to gain market acceptance;
our inability to obtain any additional required
financing; technological changes; government
regulation; changes in industry practice; and
one-time events. We do not intend to update
any of these factors or to publicly announce
the results of any revisions to these
forward-looking statements.

CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Novogen Limited, + 61.2.9878 0088
</TEXT>
</DOCUMENT>
